Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Skynet with benefits: Can AI and humans become a drug discovery superorganism?

By Brian Buntz | February 15, 2024

Doctor work with laptop computer,digital healthcare technology,system analysis network connection hologram virtual screen interface,online medical examination analysis report,banner panoramic header

[Adobe Stock]

Will the credit for future mega-blockbuster drugs, in some cases, go to a carefully-programmed AI discovery system connected to a “self-driving lab” that verified its potential?

Certainly, AI is hyped, but so are potential profits of potentially AI-optimized drugs. The exploding volumes of scientific data highlight a shift often overlooked: what does “inventor” even mean when human brilliance relies on AI and vast datasets no single person can comprehend? This future depends in part on connecting the dots between data experts, lab scientists with domain knowledge, and the machine learning systems capable of pattern recognition humans can’t even fathom. But the crux isn’t simply generating more data, and making it a shared, dynamic force fueling breakthrough discoveries — a force deeply integrated with computation and human expertise.

Breaking through the data bottleneck

Michael Connell

Michael Connell

While technologies like generative AI evolve rapidly, if data can’t keep pace, progress is limited. Today, as Enthought COO Mike Connell observes, many companies inadvertently cordon off key research findings in PDFs, PowerPoints, and Word documents. If they later decide to mine them for insights, “they have to go and search all these PowerPoints, for instance, for images,” Connell said. In other cases, they might sift through millions of PDFs with pictures of problems and known solutions. “Finding specific information in these formats isn’t possible through keyword search,” he noted.

Further complicating the picture, individual scientists might store research findings locally on laptops or in cloud storage accessible only to a small team. This decentralized approach makes it nearly impossible to establish a single source of truth, hindering knowledge sharing and collaboration. “This is not treating data as a product. It’s quite the opposite,” Connell said.

This reality often leaves researchers’ peers — or ML systems — unable to mine previously unearthed scientific insights. As research becomes ever more specialized, this inefficient hunt risks burying vital connections to fuel future scientific breakthroughs.

Skynet as lab partner: Creating a superorganism with self-improving AI and human intellect

AI’s potential in a laboratory setting extends beyond simply supporting scientists — it empowers a shift where researchers become “commanders.” In military operations, the commander’s intent is a concise statement that describes the desired endstate and purpose of the operation.

With access to the right datasets, AI systems with iterative learning could rapidly sift through past studies, spot unexpected links, and, just as Connell suggests, even propose entirely novel experiments based on a “commander’s intent.” This independence and iterative problem-solving allow the AI to analyze data, formulate strategies, and run experiments entirely driven by the directive it’s been given. Taking matters a step further, Alphabet’s DeepMind has embedded PaLM-E in robotic frameworks. Ultimately, human experts remain “commanders” — issuing objectives, validating AI discoveries, and steering its capabilities towards impactful breakthroughs.

Imagine the traditional approach of humans working step by step to devise a protocol for, say, a new leukemia treatment that targets the faulty blood cell production without the immune-suppressing side effects of chemotherapy drugs. Now, envision this: “Letting the machine find it for you through a combination of searching the data that’s out there and then running its own experiments,” Connell said.

Using AI to further AI

While the ultimate goal isn’t to hand over control to AI, AI is evolving so rapidly that it becomes increasingly necessary to use AI to make sense of, and align, other AI systems. “That’s the only way to do it, right?” Connell said. “So they’re training these other LLMs and other networks to analyze those networks. And so it’s Skynet, right?”

The Skynet dimension (or any trope involving a fictional AI gone rogue), however, can also arouse fear — and that emotion may blind some to the tool’s real-world potential. When discussing AI capable of such independence, pop culture tropes fuel anxieties, ranging from a threat to livelihood to widespread automation of tasks in bench science, data analysis, and even business decisions. On the other hand, tech optimists tend to have more of a fear of missing out on future possibilities if they delay adopting, or miss out on breakthroughs their competitors discover first through AI-accelerated research.

AI agents: Scientists’ force multipliers?

The vision of an AI-powered self-driving lab is a distinct relatively near-term possibility within drug discovery “where AI independently learns and acquires knowledge,” as a recent Nature article highlighted.

AI agents, programmed to tackle the complexities of protein analysis and compound design, hold the potential to be scientists’ force multipliers. Imagine agents capable of streamlining workflows, freeing up researchers to focus on the complexities of target identification and hypothesis generation. Or, envision an agent with the capacity for “autotelic learning” — where it sets its own goals within the scientific domain and uncovers breakthroughs that might slip past human scientists, as the aforementioned Nature article suggests.

Standing on AI shoulders

In a collaborative model, the AI isn’t simply a tool automating existing tasks; it increasingly becomes a source for human knowledge — a new sort of summit to stand on. When asked what allowed him to break new intellectual ground, Isaac Newton quipped, “If I have seen further than others, it is by standing upon the shoulders of giants.” The same principle often holds for AI agents whose knowledge is based on the tireless work of human researchers. This foundation can become a launchpad for further discovery where well-designed AI systems synthesize information at a scale inconceivable to individual minds. As Pierre-Yves Oudeyer stated in Nature, “agents could form the basis of embodied intelligence, which might eventually lead to self-driving labs where AI independently learns and acquires knowledge.”

Michelle Longmire

Dr. Michelle Longmire

In a recent episode of AI Meets Life Sci, Dr. Michelle Longmire, CEO of Medable, painted a sobering picture: “Right now, at the current pace, there are approximately 10,000 uncured or poorly suboptimally treated human diseases, it’s going to take us about 200 years to create treatments for all of those different conditions.” However, she envisioned a radical shift: “Imagine if we could 10x that… then that timeline goes from 200 years to 20 years, something potentially feasible in most of our lifetimes.”

Making such a vision a reality won’t be possible with siloed AI systems, fragmented data or isolated researchers storing valuable findings in isolated spreadsheets or PowerPoints. “There’s an enormous amount of latent value out there that’s inaccessible,” Connell said. It’s hard to fathom the value hidden in obscure patents, past failed research, even overlooked older academic work.

Unshackling untapped data fuel

While much has been made of the exploding volumes of data in medical and scientific research, much data is frequently underutilized. If we don’t treat data as “a valuable resource… as a data product,” as Connell urged, neither human researchers nor AI can leverage it. Instead of fearing the emergence of a real-world Skynet, a more productive strategy is to step up and play an active role in deploying and aligning AI systems with altruistic values.

This shift wouldn’t just transform labs, but our approach to knowledge itself. “Imagine a drug discovery lab where the traditional focus on individual researchers is replaced by interconnected agents,” Connell said. We could break down tasks currently carried out by humans, allowing the lab to become something fundamentally different — a kind of advanced “computing box,” as Connell put it. Yes, it analyzes data, but it also acts upon the physical world, creating and testing new compounds in a sort of closed loop. With AI tireless and free from some of the pitfalls inherent to human work, this shift lets us rethink science — and the creation of research literature and data — at a higher level. Perhaps instead of focusing on specific steps, entire experiments could be designed, refined, and shared seamlessly with other labs worldwide.

It’s not overlord AI we should fear — it’s human inertia

Skynet was self-contained, seeking knowledge independently. The aim isn’t to base tangible AI plans on science fiction tropes, but to build something fundamentally collaborative and carefully aligned to altruistic aims. Maybe the fear of Skynet isn’t the AI getting too smart, but us becoming intellectually inert as it does our grunt work. Avoiding this scenario requires laying the foundation for a reality in which data, computing, humans and algorithms are aligned in a way that is mutually beneficial and self-correcting. This is Skynet, reimagined.


Filed Under: Biotech, Data science, machine learning and AI
Tagged With: AI in drug discovery, AI-driven research, Biotech Innovations, Drug Development Technology, Machine Learning in Pharma, Pharmaceutical AI, Self-Driving Labs
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Capgemini’s life-sciences lead says ROI and data security, not algorithms, will decide pharma’s AI future
Portrait of happy smiling mature middle aged professional business woman investor manager executive or lawyer attorney looking at camera at workplace working on laptop computer in office.
As FDA pushes agency-wide generative AI, pharma experience show similar tools can cut clinical study-report drafting time by 30% or more
FDA’s genAI push could save CDER hundreds of thousands of review hours annually
Elsevier plugs 500,000 ClinicalTrials.gov records into Embase
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE